Gaviscon — Class III drug recall D-0926-2017
Terminated recall by Sanofi-Aventis U.S. LLC, reported 2017-07-05, distributed nationwide. Superpotent Drug: high out-of-specification result for magnesium.
| Recall number | D-0926-2017 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Sanofi-Aventis U.S. LLC, Bridgewater, NJ, United States |
| Recall initiated | 2017-06-12 |
| Classified | 2017-06-29 |
| Reported by FDA | 2017-07-05 |
| Terminated | 2019-02-07 |
| Distributed | Nationwide (US) |
| Countries outside the US | GB |
| Quantity | 2,980 bottles |
| Reason classes | potency |
| NDC | 00088-1175-47 |
| Lot numbers | 02/19, 08/19, 5J69A, 6GF2A, 6GF3A |
Product
Gaviscon (Alumina & Magnesium Trisilicate) Regular Strength Original Flavor Chewable Tablets, 80 mg & 14.2 mg, 100-count bottles, Distributed by: GlaxoSmithKline Consumer Healthcare, L.P., Moon Twp, PA 15108, UPC 3 0088-1175-47 8.
Reason for recall
Superpotent Drug: high out-of-specification result for magnesium.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0926-2017. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.